Find an MSK Doctor or Cancer Specialist
Yingbei Chen, MD, PhD

Yingbei Chen, MD, PhD

Pathologist

My Role at MSK

Areas of Expertise

My Specialties

  • Genitourinary Pathology
View all
Dr. Chen's Office Information
Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
Back to top
English
Share

About Me

What I Do at MSK
  • Attending Pathologist
My Role at MSK

A pathologist is a doctor who uses a microscope to make a diagnosis from cell and tissue samples. They analyze the samples to learn the cause and effects of a health condition.

Areas of Expertise

My Specialties

  • Genitourinary Pathology
Education & Honors

Education

  • MD, Peking Union Medical College (China)
  • PhD, The Johns Hopkins School of Medicine

Residencies

  • NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Fellowships

  • The Johns Hopkins Hospital

Board Certifications

  • Anatomic and Clinical Pathology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA and NYC retirees only)

In Network Coverage Type
PPO

Anthem BCBS and other BCBS licensee plans

In Network Coverage Type
PPO, POS, EPO, HMO

See updates

Anthem BCBS Health Plus

In Network Coverage Type
HMO

See updates

Anthem Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

See updates

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

See updates

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

See updates

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)

In Network Coverage Type
PPO, HMO

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

See updates

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

See updates

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

See updates

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

See updates

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Request an Opinion

Women talking

Request an Opinion

We can assess your case without an appointment. Click or call 212-639-6780— Monday through Friday, to (Eastern time)
Get a Consultation

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Chen sees patients at one location.

Office Phone
Location
New York, NY
Memorial Sloan Kettering Cancer Center
1275 York Avenue New York NY 10065
Get Directions

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Surgical Pathology doctors

See all Genitourinary Pathology doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Chen YB, Aon MA, Hsu YT, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O’Rourke B, Ko YH, Pedersen PL, Kaczmarek LK, Jonas EA, Hardwick JM. Bcl-xlL regulates mitochondrial energetics by stabilizing the inner membrane potential. Journal of Cell Biology 2011; 195(2):263-76.

Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, Lazrove E, Nabili P, Flaherty B, Graham M, Chen YB, Messerli SM, Mariggio MA, Rahner C, McNay E, Shore GC, Smith PJ, Hardwick JM, Jonas EA.  Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FoATP synthase. Nature Cell Biology 2011; 13(10):1224-33.

Read more

Chen YB, Fine SW, Epstein JI. Mesonephric Remnant Hyperplasia Involving Prostate and Periprostatic Tissue: Findings at Radical Prostatectomy. American Journal of Surgical Pathology 2011; 35(7):1054-61.

Przybycin CG, Cronin AM, Darvishian F, Gopalan A, Al-Ahmadie HA, Fine SW, Chen YB, Bernstein M, Russo P, Reuter VE, Tickoo SK. Chromophobe Renal Cell Carcinoma: A Clinicopathologic Study of 203 Tumors in 200 Patients With Primary Resection at a Single Institution. American Journal of Surgical Pathology 2011; 35(7):962-70.

Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK, Fine SW, Gopalan A, Chen YB, Balar A, Riches J, Bochner B, Dalbagni G, Bajorin DF, Reuter VE, Milowsky MI, Solit DB.  Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. Journal of Pathology 2011; 224(2):270-9.

Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. American Journal of Surgical lPathology 2011; 35(3):442-6.

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010; 116(23):5517-26.

Rickman DS*, Chen YB*, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR, Sircar K, Chinnaiyan AM, Bismar TA, Rubin MA, Demichelis F. ERG cooperates with androgen receptor in regulating trefiol factor 3 in prostate cancer disease progression. Neoplasia 2010; 12(12):1031-40 (*equal contribution).

Chen YB, Pierorazio PM, Epstein JI. Initial atypical diagnosis with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy. Journal of Urology 2010; 184(5):1953-7.

Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine 2010; 16(7) :7793-8

Miller JS, Chen YB, Ye H, Robinson BD, Brimo F and Epstein JI. Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: repoprt of 72 case with clinical follow-up. BJU International 2010; 106(3):330-3.

Berman SB, Chen YB, Qi B, McCaffery JM, Rucker EB 3rd, Goebbels S, Nave KA, Arnold BA, Jonas EA, Pineda FJ, Hardwick JM. Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons. Journal of Cell Biology 2009; 184(5) :707-19

Chen YB, Tu JJ, Kao J, Zhou XK, Chen YT.. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Archives of Pathology and Laboratory Medicine 2008; 132(2) :224-31

Chen YB, Magpayo J, Rosen PP.. Sclerosing adenosis in sentinel axillary lymph nodes from a patient with invasive ductal carcinoma: an unusual variant of benign glandular inclusions. Archives of Pathology and Laboratory Medicine 2008; 132(9) :1439-41

Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R, McNay EC, Yu T, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MV, Pypaert M, Hickman JA, Smith PJ, Hardwick JM, Jonas EA.. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. PNAS 2008; 105(6) :2169-74

Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM.. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.. Hepatology 2007; 45(4) :938-47

Chen YB, Seo SY, Kirsch DG, Sheu TT, Cheng WC, Hardwick JM.. Alternate functions of viral regulators of cell death. Cell Death Differentiation 2006; 13(8) :1318-24

Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL.. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131(6) :1758-67

Zhang J, Chen YB, Hardwick JM, Miller MI, Plachez C, Richards LJ, Yarowsky P, van Zijl P, Mori S.. Magnetic resonance diffusion tensor microimaging reveals a role for Bcl-x in brain development and homeostasis.. Journal Of Neuroscience 2005; 25(8) :1881-8

Seo SY, Chen YB, Ivanovska I, Ranger AM, Hong SJ, Dawson VL, Korsmeyer SJ, Bellows DS, Fannjiang Y, Hardwick JM.. BAD is a pro-survival factor prior to activation of its pro-apoptotic function. Journal of Biological Chemistry 2004; 279(40) :42240-9

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yingbei Chen discloses the following relationships and financial interests:

  • Inspirna, Inc.
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: